Literature DB >> 9841738

A new structural model for P-glycoprotein.

P M Jones1, A M George.   

Abstract

Multidrug resistance to anti-cancer drugs is a major medical problem. Resistance is manifested largely by the product of the human MDR1 gene, P-glycoprotein, an ABC transporter that is an integral membrane protein of 1280 amino acids arranged into two homologous halves, each comprising 6 putative transmembrane alpha-helices and an ATP binding domain. Despite the plethora of data from site-directed, scanning and domain replacement mutagenesis, epitope mapping and photoaffinity labeling, a clear structural model for P-glycoprotein remains largely elusive. In this report, we propose a new model for P-glycoprotein that is supported by the vast body of previous data. The model comprises 2 membrane-embedded 16-strand beta-barrels, attached by short loops to two 6-helix bundles beneath each barrel. Each ATP binding domain contributes 2 beta-strands and 1 alpha-helix to the structure. This model, together with an analysis of the amino acid sequence alignment of P-glycoprotein isoforms, is used to delineate drug binding and translocation sites. We show that the locations of these sites are consistent with mutational, kinetic and labeling data.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9841738     DOI: 10.1007/s002329900455

Source DB:  PubMed          Journal:  J Membr Biol        ISSN: 0022-2631            Impact factor:   1.843


  7 in total

1.  Molecular cloning and characterization of an ABC multidrug efflux pump, VcaM, in Non-O1 Vibrio cholerae.

Authors:  Nazmul Huda; Eun-Woo Lee; Jing Chen; Yuji Morita; Teruo Kuroda; Tohru Mizushima; Tomofusa Tsuchiya
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

Review 2.  Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators.

Authors:  Ahmad R Safa
Journal:  Curr Med Chem Anticancer Agents       Date:  2004-01

3.  Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma.

Authors:  Heidi Schwarzenbach
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

4.  MDR1 Ala893 polymorphism is associated with inflammatory bowel disease.

Authors:  Steven R Brant; Carolien I M Panhuysen; Dan Nicolae; Deepthi M Reddy; Denise K Bonen; Reda Karaliukas; Leilei Zhang; Eric Swanson; Lisa W Datta; Thomas Moran; Geoffrey Ravenhill; Richard H Duerr; Jean-Paul Achkar; Amir S Karban; Judy H Cho
Journal:  Am J Hum Genet       Date:  2003-11-07       Impact factor: 11.025

Review 5.  Comparison of mechanistic transport cycle models of ABC exporters.

Authors:  Dániel Szöllősi; Dania Rose-Sperling; Ute A Hellmich; Thomas Stockner
Journal:  Biochim Biophys Acta Biomembr       Date:  2017-10-31       Impact factor: 3.747

Review 6.  Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators.

Authors:  Silvia Dei; Laura Braconi; Maria Novella Romanelli; Elisabetta Teodori
Journal:  Cancer Drug Resist       Date:  2019-09-19

7.  Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor.

Authors:  Sai-Qi Wang; Qiu-Xu Teng; Shuai Wang; Zi-Ning Lei; Hui-Hui Hu; Hui-Fang Lv; Bei-Bei Chen; Jian-Zheng Wang; Xiao-Jing Shi; Wei-Feng Xu; Hong-Min Liu; Xiao-Bing Chen; Zhe-Sheng Chen; Bin Yu
Journal:  Acta Pharm Sin B       Date:  2022-04-02       Impact factor: 14.903

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.